Clinical trials in sickle cell disease: Adopting the combination chemotherapy paradigm

American Journal of Hematology

Volumn 83, Issue 1, 2008, Pages 1-3

  Steinberg, Martin H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARGINASE; ENDOTHELIN; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PYROGLUTAMATE MAGNESIUM; SALAZOSULFAPYRIDINE;

AMINO ACID SUBSTITUTION; CATION TRANSPORT; CELL ACTIVATION; DRUG POTENTIATION; EDITORIAL; ENDOTHELIUM CELL; GENE DELETION; GENE MUTATION; GENE THERAPY; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMERIZATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION;

ANEMIA, SICKLE CELL; ANIMALS; CELL ADHESION; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; NITRIC OXIDE;

EID: 38349066166     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21033     Document Type: Editorial

References (46)

1. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature 1956;178:792-794.
2. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2006;21:37-47.
3. Hebbel RP, Osarogiagbon UR, Kaul D. The endothelial biology of sickle cell disease: Inflammation and a chronic vasculopathy. Microcirculation 2004;11:129-152.
4. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol 2005;129:465-481.
5. Brugnara C. Sickle cell disease: From membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. J Pediatr Hematol Oncol 2003;25:927-933.
6. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-1389.
7. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
8. Gladwin MT. Unraveling the hemolytic subphenotype of sickle cell disease. Blood 2005;106:2925-2926.
9. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood 2005;106:3264-3267.
10. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: Associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-β/BMP pathway. Br J Haematol 2006;133:570-578.
11. DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-895.
12. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
13. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002;99:10-14.
14. Bakanay SM, Dainer E, Clair B, et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood 2004;105:545-547.
15. Koshy M, Dorn L, Bressler L, et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000;96:2379-2384.
16. Bohacek R, Boosalis MS, McMartin C, et al. Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models. Chem Biol Drug Des 2006;67:318-328.
17. Pace BS, White GL, Dover GJ, et al. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood 2002;100:4640-4648.
18. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999;93:1790-1797.
19. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997;100:1847-1852.
20. Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996;97:1227-1234.
21. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991;325:1476-1481.
22. Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2003;289:1136-1142.
23. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69.
24. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 2006;67:1043-1048.
25. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005;130:445-453.
26. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: A pilot study. Blood 2001;97:1937-1941.
27. Kaul DK, Liu XD, Choong S, et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol 2004;287:293-301.
28. Reiter CD, Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 2003;10:99-107.
29. Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med 2006;41:1771-1780.
30. Kaul DK, Kollander R, Mahaseth H, et al. Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation. Microcirculation 2006;13:489-497.
31. Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004;104:840-846.
32. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: Mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 2005;19:881-896.
33. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002;100:3790-3796.
34. Kaul DK, Liu XD, Zhang X, et al. Peptides based on αV-binding domains of erythrocyte ICAM-4 inhibit sickle red cell-endothelial interactions and vasoocclusion in the microcirculation. Am J Physiol Cell Physiol 2006;291:C922-C930.
35. Turhan A, Jenab P, Bruhns P, et al. Intravenous immune globulin prevents venular vaso-occlusion In sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 2004;103:2397-2400.
36. Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm. Proc Natl Acad Sci USA 2002;99:3047-3051.
37. Steinberg MH, Rosenstock W, Coleman MB, et al. Effects of thalassemia and microcytosis upon the hematological and vaso-occlusive severity of sickle cell anemia. Blood 1984;63:1353-1360.
38. Adams RJ, Kutlar A, McKie V, et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol 1994;45:279-282.
39. 2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci USA 1993;90:5039-5043.
40. DeSimone J, Heller P, Hall L, Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemia baboons. Proc Natl Acad Sci USA 1982;79:4428-4431.
41. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652-656.
42. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia - Clinical utility of a myelosuppressive "switching" agent. Medicine (Baltimore) 1996;75:300-326.
43. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651.
44. Sebastiani P, Nolan VG, Baldwin CT, et al. Predicting severity of sickle cell disease. Blood 2007; June 28 epub.
45. Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005;37:435-440.
46. Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: Genetic determinants of response to hydroxyurea. Pharmacogenomics J 2007; February 13 epub.